As per the agreement, GP Pharm Mexico will be responsible for gaining regulatory approval in Mexico for Ampligen, an experimental therapeutic, to treat Chronic Fatigue Syndrome (CFS) in Mexico and for commercialising Ampligen for this indication in Mexico.
The company has granted GP Pharm the right to expand rights to sell this experimental therapeutic into other Latin America countries based upon GP Pharm achieving certain performance milestones.
Hemispherx executive vice chairman Thomas Kenwood Equels said that they are very pleased by the diligent efforts of GP Pharm in Argentina and encouraged that GP Pharm Mexico is prepared to undertake efforts immediately to gain approval and commercialise Ampligen for CFS in Mexico.